HERPES ZOSTER NOVEL TREATMENT HOPE FROM TASMANIAN ABALONE GETS $1.2 MILLION BOOST

Sydney, Australia, 23 May 2011 – Leading Australian contract clinical research company Novotech, Marine Biotechnology Australia Pty Ltd [MBA] and the University of Sydney today announced a new Herpes research collaboration backed by the Academic Research Council [ARC]. The team aims to commercialize a novel treatment for Herpes simplex and Herpes zoster utilizing an extract [...]

Novotech initiates cancer trials in Australia and New Zealand for Oncomed Pharmaceuticals

NOVOTECH  INITIATES PHASE IB CANCER TRIALS IN AUSTRALIA AND NEW ZEALAND FOR CLIENT, ONCOMED PHARMACEUTICALS Sydney, Australia, 29 October 2010 – Novotech has announced initiation of three Phase Ib oncology trials at sites in Australia and New Zealand to test the safety, efficacy and pharmacokinetics of client OncoMed’s humanized monoclonal antibody product designed to target [...]

Novotech Selects Oracle’s Siebel Clinical Trial Management System to Support Continued Growth

Novotech Selects Oracle’s Siebel Clinical Trial Management System to Support Continued Growth Sydney, Australia – 27 October, 2010 News Facts Novotech, the largest independent clinical research organisation in Australia, has selected Oracle’s Siebel Clinical Trial Management System to support the company’s complete spectrum of clinical drug development and research. Novotech works with leading biotechnology and [...]

Novotech CEO to speak on Clinical Projects – Faster and Smarter it’s All in the Planning at the 46th DIA Annual Meeting June 13-17 in Washington, DC

Washington, DC, June 13, 2010 – Leading Australian contract clinical research company Novotech announced today that Novotech CEO Alek Safarian will be sharing the company’s Asia Region expertise and experience at DIA 2010 to be held in Washington, DC. Safarian will speak on “Global Study Experiences: Lessons from Observing Regional Variations” which is part of [...]

Novotech embarks on a new strategic partnership with Citeline, designed to accelerate patient recruitment and complete clinical studies more quickly.

Novotech embarks on a new strategic partnership with Citeline, designed to accelerate patient recruitment and complete clinical studies more quickly. NEW YORK – 15/4/10 – Novotech, a leading Australasian CRO, has engaged Citeline to support its clinical development programs and further improve the rate at which Sponsor clinical studies are planned and carried out. Citeline, [...]

Novotech announces four country Asia expansion at AusBiotech 2009

NOVOTECH ANNOUNCES FOUR COUNTRY ASIA EXPANSION AT AUSBIOTECH 2009 New operations in Malaysia, Singapore, Thailand, and Philippines Sydney, Oct 27, 2009 – Leading Australian contract clinical research company Novotech announced today that it was expanding into four new Asian markets with the establishment of a management hub in Kuala Lumpur, Malaysia. Novotech CEO Alek Safarian [...]

New Study of Investigational Alzheimer’s Disease Treatment Enrolling Patients in Australia

New Study of Investigational Alzheimer’s Disease Treatment Enrolling Patients in Australia Sydney, Australia – 31, August 2009 – It was announced today that a new global clinical trial has begun enrolling patients with Alzheimer’s disease in NSW, Victoria, Queensland, South Australia, and Western Australia. The CONCERT study, is a new clinical trial that will test [...]

Novotech wins coveted Australian CRO Award from Frost & Sullivan

San Diego, CA– June 19, 2008 — Novotech, the largest Australian owned contract research organization (CRO) has confirmed its position as the pre-eminent Australian based CRO with the award by leading industry analyst house Frost & Sullivan as the Australian CRO of the Year. The award is part of the prestigious Excellence in Healthcare Awards [...]

Athletes, and non-athletes, between 18 and 65 wanted for tinea study

ATHLETES’ FOOT AFFECTS MORE THAN 9% OF PEOPLE Sydney, Australia – November 17, 2007 – A novel new oral treatment for Tinea, commonly known as Athletes’ Foot, is now being tested by Australian research teams in Melbourne, Sydney, Adelaide and Brisbane as part of a global study in the condition that affects over 9% of [...]

Australian research teams test prawn shell treatment to combat hayfever

“DRUG FROM THE SEA” SHOWS POTENTIAL FOR ALLERGY SUFFERERS Sydney, Australia – November 14, 2007 – A novel agent for the treatment of rhinitis, commonly known as hayfever, is now being tested by Australian research teams in Melbourne, Sydney, and Brisbane. The agent is derived from the shells of marine crustaceans. Dr Rimmer from the [...]

Next Page »